MIDAZOLAM INJECTION
As listed in the register: MIDAZOLAM INJECTION, USP
5 mg · solution
- Prescription only
- Pain, sleep, mood, epilepsy and the brain
- Active substance
- Midazolam
- Made by
- Fresenius Kabi Canada Ltd
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Nayzilam). It describes the substance, not this exact product.
The exact mechanism of action for midazolam is not fully understood, but it is thought to involve potentiation of GABAergic neurotransmission resulting from binding at the benzodiazepine site of the GABA A receptor.
Midazolam is primarily metabolized by liver and intestinal cytochrome P450 3A4 (CYP3A4) to its pharmacologic active metabolite, 1-hydroxy midazolam (also termed α-hydroxy-midazolam).
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2023-01-19
Safety of the active substance
From the US prescribing label for the same active substance (Nayzilam). It describes the substance, not this exact product.
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death.
- NAYZILAM is contraindicated in patients with: Known hypersensitivity to midazolam.
- Acute narrow-angle glaucoma [see Warnings and Precautions (5.8) ].
- Patients with hypersensitivity to midazolam ( 4 ) Patients with acute narrow-angle glaucoma ( 4 )
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
FranceNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Fresenius Kabi Canada Ltd |
|---|---|
| Active substance | Midazolam |
| Used in | Pain, sleep, mood, epilepsy and the brain |
| Strength | 5 mg |
| Form | solution |
| Classification | N05CD08 · Pain, sleep, mood, epilepsy and the brain |
| Route | intramuscular, intravenous |
| Dispensing (as stated by the register) | TARGETED SUBSTANCES (CDSA IV) |
| Status | Marketed |
| Marketed | Yes, according to the register |
| Name in the register | MIDAZOLAM INJECTION, USP |
| DIN | 02242905 |
| DPD drug code | 66737 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
6 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
- solution6 products
1 mg3
1 mg · 3 companies
5 mg3
5 mg · 3 companies
- Baxter Corporation
- Fresenius Kabi Canada Ltd · this page
- Sandoz Canada Incorporated
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.